Evidence map›Paper›PMID 40455746›Full record

ArticlePloS one2025

AD-GCN: A novel graph convolutional network integrating multi-omics data for enhanced Alzheimer's disease diagnosis.

Zilu Li, Qingyun Li, Xiaoqing Li, Wei Luo, Haiyan Guo, Chunyan Zhao, Canzhen Yang, Anke Xie, Kai Hu, Yangfan Guo

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. From molecules to minds: Integrative multi-omics in psychiatry.Journal of mood and anxiety disorders · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zilu LiFaculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming, China.ORCID https://orcid.org/0009-0009-2942-1072
Qingyun LiNeurology Department of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Xiaoqing LiCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Wei LuoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Haiyan GuoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Chunyan ZhaoNeurology Department of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Canzhen YangNeurology Department of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
Anke XieYunnan Innovation Institute of Beihang University, Kunming, China.
Kai HuYunnan Innovation Institute of Beihang University, Kunming, China.
Yangfan GuoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.ORCID https://orcid.org/0009-0004-0060-2957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) etiology is complex, influenced by demographic risk factors such as age, sex, and educational level, alongside multi-omics factors derived from genomics, transcriptomics, and epigenomics. Advancements in multi-omics technology present both challenges and opportunities for AD diagnosis, enabling a more comprehensive understanding of the complex interactions among contributing factors, with the goal of improving diagnostic accuracy. To address this challenge, we propose a novel feature fusion approach in this study, AD-GCN, which integrates multi-omics data and their interaction networks to achieve more precise diagnosis and analysis of AD. In this study, we applied polygenic risk score and random forest algorithms for feature selection on genetic variation and methylation data. We then developed an AD-GCN for both multi-omics and single-omics classification tasks and compared its performance with that of machine learning ensemble methods. The experimental results demonstrated that multi-omics classification significantly outperformed single-omics classification, with AD-GCN surpassing the machine-learning ensembles. These findings highlight AD-GCN's strong potential to enhance AD diagnosis and improve accuracy in differentiating disease stages by integrating interactions across omics data, laying a solid foundation for the development of more precise and personalized AD diagnostic models.

Indexed as

Alzheimer DiseaseGenomicsAlgorithmsDNA MethylationEpigenomicsFemaleHumansMachine LearningMaleMultiomicsNeural Networks, Computer

Identifiers

PMID40455746
PMCPMC12129192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.